Viatris Q1 revenues $3.5B (+8% YoY), adj. EBITDA $1.0B, reaffirms FY guidance

Viatris Inc

2026-Q1 EPS reported $0.15 revenue$3,517,000,000

Total revenues $3.5B, up 8% reported and 3% operational vs Q1 2025.
US GAAP net earnings $176M; Adjusted EBITDA $1.0B, +10% operationally.
Reaffirms 2026 financial guidance; expects >$2.5B cash available for deployment.
Launched Effexor for generalized anxiety disorder in Japan; pipeline milestones progressing.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Viatris Inc updated its first-quarter 2026 guidance (reaffirmed).

Period: first-quarter 2026
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 7, 2026 , Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Viatris Inc filing history →

Source: SEC EDGAR

accession 0001792044-26-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.